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ABSTRACT
Radiation therapy provides a means to kill large numbers of cancer cells in a 
controlled location resulting in the release of tumor-specific antigens and endogenous 
adjuvants. However, by activating pathways involved in apoptotic cell recognition 
and phagocytosis, irradiated cancer cells engender suppressive phenotypes in 
macrophages. We demonstrate that the macrophage-specific phagocytic receptor, 
Mertk is upregulated in macrophages in the tumor following radiation therapy. 
Ligation of Mertk on macrophages results in anti-inflammatory cytokine responses 
via NF-kB p50 upregulation, which in turn limits tumor control following radiation 
therapy. We demonstrate that in immunogenic tumors, loss of Mertk is sufficient 
to permit tumor cure following radiation therapy. However, in poorly immunogenic 
tumors, TGFa inhibition is also required to result in tumor cure following radiation 
therapy. These data demonstrate that Mertk is a highly specific target whose absence 
permits tumor control in combination with radiation therapy.
INTRODUCTION
High-dose radiation has the ability to produce large-
scale cancer cell death at the tumor site over a short time 
frame [1]. Cancer cell death has the potential to provide 
both antigen and the immunological adjuvants required 
for effective adaptive immune responses [2]. For these 
reasons, it has been proposed that killing cancer cells in 
a way that releases both antigen and adjuvant, so called 
immunogenic cell death, could generate more effective 
adaptive immune responses to tumor antigens. For this 
immune priming effect to be fully functional, it is critical 
to consider both the way that cancer cells die [3], the 
mix of immune cells in the vicinity of dying cancer cells 
[4, 5], and it is just as critical to consider the impact of 
radiation directly on the immune cells. This is particularly 
relevant since cell-associated antigen and adjuvant are 
commonly released from many tumors: necrotic foci are 
frequently observable in advanced cancers [6], and uric 
acid, which has been shown to act as an immune adjuvant 
[7], is frequently elevated in the blood of cancer patients 
receiving cytotoxic therapy. These data would suggest 
that tumor antigen-specific immune responses should be 
efficiently generated by most large tumors with necrotic 
foci without additional treatment, or each time cytotoxic 
therapy is delivered. However, evidence suggests that 
adaptive immune responses to tumors are not constantly 
growing in strength, by contrast in the absence of 
additional intervention, adaptive immune responses to 
tumors may be present but are generally ineffective in 
tumor control [8-11].
To understand this disconnect, it is important to 
appreciate that there are simultaneous negative signals 
that influence the response to adjuvant and thereby limit 
adaptive immune responses against tumor antigens in vivo. 
As tumors progress in mice and in patients there is a 
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progressive macrophage infiltration that has been shown 
to be critical for tumor angiogenesis, progression and 
metastatic spread in mice [12, 13] and is associated with 
poor prognosis in patients [14]. There is often a reciprocal 
relationship between T cell infiltration and macrophage 
infiltration in tumors, and where T cells are low and 
macrophages are high, the prognosis is especially poor [15, 
16]. Tumor macrophages are generally differentiated into 
phenotypes that can suppress T cell activation [17], and 
treatment of these tumor macrophages with immunological 
adjuvants results in production of anti-inflammatory rather 
than pro-inflammatory cytokines [18]. In addition to this 
pre-disposition of tumor macrophages, dying cells are 
efficiently immunosuppressive in vitro and in vivo. In 
vitro, apoptotic cells drive differentiation of macrophages 
into suppressive phenotypes that involve secretion of 
anti-inflammatory cytokines such as TGFβ and IL-10 and 
upregulation of suppressive molecules such as Arginase I 
[19-21]. In vivo, systemic administration of apoptotic cells 
is an efficient means to generate antigen-specific tolerance 
[22, 23].
Mertk, along with Tyro3 and Axl, are members of 
the TAM (Tyro3-Axl-Mertk) subgroup of receptor tyrosine 
kinases. The dominant ligand for Mertk is Gas6, a protein 
S-related gene that has been shown to bind exposed 
phosphatidylserine (PS) on apoptotic cells. The Mertk-
Gas6-PS interaction results in phagocytosis of the apoptotic 
cell [24], and mice with inactivated Mertk are defective in 
their handling of apoptotic cells [25, 26]. Complete loss 
of Mertk and its family members Akt and Tyro3 results 
in pro-inflammatory patterns of gene expression and 
loss of immune privilege [27, 28]. Additionally, mice 
with inactivated Mertk are also hypersensitive to LPS 
stimulation [29], suggesting that in the steady state, Mertk 
delivers a negative regulatory signal. Mertk-dependent 
uptake of dying cells results in signal transduction that 
suppresses macrophage inflammatory responses resulting 
in strong immune tolerance to antigens that are taken 
up via Mertk ligation [30]. A number of other bridging 
molecules have been identified that have the capacity to 
link apoptotic cells to macrophages (reviewed in [31]). 
The relative contribution of the different adaptor molecules 
remains to be determined since where large-scale death 
occurs disruption of any one of these interactions may be 
sufficient to alter the handling of dying cells. However, 
unlike many other characterized receptors Mertk has the 
capacity to transduce signals to the macrophage and is the 
signaling component of phagocytic complexes involving 
MFGE8 [32] and C1q [33]. In some circumstances, 
these positive signals may be countered by phosphatases 
activated by CD47 ligation of SIRPa to block phagocytosis 
(reviewed in [34]). Thus, while a range of molecules may 
be involved in macrophage binding of opsonized apoptotic 
cells, there is evidence that Mertk in macrophages may 
play a central role in signal transduction following binding.
We and others have demonstrated increased 
infiltration of macrophages into tumors following radiation 
therapy [18, 35-38], and that these macrophages exhibited 
increased suppressive differentiation in the post-treatment 
tumor environment [18]. In studying the gene expression 
patterns of tumor infiltrating macrophages, we identified 
upregulation of Mertk in tumor macrophages following 
radiation therapy. We demonstrate here that ligation of 
Mertk on macrophages recapitulates the suppressive effect 
of dying cells and that blocking Mertk interaction with 
irradiated cancer cells blocks suppressive differentiation 
of tumor macrophages. Using CT-guided radiation to treat 
tumors in immune competent mice, we demonstrate that in 
immunogenic tumors, radiation therapy is curative in mice 
lacking Mertk. In poorly immunogenic tumors, loss of 
Mertk is not sufficient to change the response to radiation 
therapy, but when combined with blockade of TGFβR 
results in tumor cures. These data demonstrate that Mertk 
is a strong therapeutic target to permit tumor clearance by 
radiation therapy.
RESULTS
A number of investigators have demonstrated that 
macrophages are recruited to tumors following radiation 
therapy and limit tumor control [18, 35-38]. These 
macrophages are polarized to M2 phenotypes determined 
by differentiation marker expression and gene array analysis 
of CD11b+Gr1loIA+ macrophages sorted from untreated 
and irradiated tumors [18]. Since phagocytosis of dying 
cells is known to drive M2 differentiation of macrophages 
[19-21], we analyzed our dataset for genes involved in 
phagocytosis pathways that are significantly changed 
following radiation therapy (Figure 1ai-ii). Amongst this 
set of genes, it was noticeable that the phagocytic receptor 
for apoptotic cells Mertk was significantly upregulated 
early following radiation therapy, as was its ligands Gas6 
and protein S (Pros1) (Figure 1aii). As a member of the 
TAM family of receptor tyrosine kinases, Mertk is known 
to play a significant role in the phagocytosis of dying 
cells. Interestingly, Mertk has been described as one of 
the most specific genes to distinguish macrophages from 
dendritic cells [49]. Comparative analysis of the TAM 
family members and Gas6 in the broad panel of immune 
cells made available through the Immunological Genome 
Project Consortium (www.immgen.org) shows that 
Mertk is highly restricted to macrophages, while Axl has 
slightly wider expression and Tyro3 is poorly expressed 
(Figure 1b). By grouping macrophage and other myeloid 
subtypes within the Immunological Genome Project 
Consortium dataset, it is clear that Mertk expression is 
highly restricted to macrophages, with above 20 fold 
higher expression on collected macrophage subtypes than 
dendritic cell subtypes, neutrophil subtypes or monocyte 
subtypes (Figure 1c). These data suggest that Mertk is 
a strong candidate as a target molecule on macrophages 
involved in responses to dying cells in the irradiated tumor.
To understand how the phagocytic receptor Mertk 
may cause changes in macrophages, we examined 
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the response to Mertk ligation in vitro. Bone marrow 
macrophages generated through culture in M-CSF were 
confirmed to express Mertk by immunofluorescence (data 
not shown). Treatment with Gas6 caused VEGF secretion 
in bone marrow macrophages (Figure 2ai) and suppressed 
the ability of macrophages to secrete TNFα (not shown) 
and IL-12 in response to LPS stimulation (Figure 2aii). 
To determine whether Gas6 could cause differentiation of 
macrophages into M1 or M2 patterns of gene expression, 
bone marrow macrophages were treated with Gas6 
for 24 hours alongside controls treated with IFNγ and 
LPS to drive M1 differentiation, or IL-4 to drive M2 
differentiation. Gas6 was unable to drive induction of the 
M1 marker iNOS or the M2 marker Arginase (Figure 2b). 
These data demonstrate that Mertk ligation affects 
cytokine responses without affecting expression of the 
prototypical markers of M1 and M2 differentiated cells.
Macrophages have been shown to change their 
cytokine response to stimulation through a change in the 
level of NFκB p50 in cells, as a result of signaling through 
NFκB p50 homodimers rather than conventional NFκB 
p50:p65 heterodimers [50] and we have demonstrated 
that NFκB1-/- macrophages do not change their cytokine 
response in the presence of irradiated cancer cells [18]. 
Thus, alteration in NFκB p50 is a potential signaling 
mechanism to repolarize cytokine responses without 
changing differentiation. To confirm that Mertk signaling 
results in activation of the MEK-ERK-Tpl2- NFκB p105 
complex, bone-marrow macrophages from wild-type or 
Mertk-/- mice were treated with Gas6 and first analyzed for 
Erk phosphorylation. Gas6 increased Erk phosphorylation 
in wild-type, but not Mertk-/- macrophages (Figure 2c), 
and 24 hours of treatment with Gas6 resulted in 
accumulation of NFκB p50 in wild-type but not Mertk-/- 
macrophages (Figure 2d). To determine whether the 
cytokine response was due to the effects of NFκB p50, 
wild-type macrophages were treated with a cell-permeable 
NFκB p50 inhibitor peptide or a control peptide, and 
treated with Gas6. The presence of the NFκB p50 inhibitor 
significantly reduced VEGF induction (Figure 2e) 
while simultaneously increasing TNFα production (not 
shown) consistent with our prior studies using NFκB1-/-
 macrophages [18]. In addition, Gas6 treatment did not 
induce VEGF in Mertk-/- macrophages (not shown). To 
examine the role of myeloid expression of NFκB p50 in 
the response to radiation therapy, we established bone 
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Figure 1: Upregulation of the macrophage-specific phagocytic receptor Mertk following radiation therapy of tumors. 
a. CD11b+Gr1loIA+ macrophages sorted from untreated and irradiated tumors were subjected to gene expression analysis (GEO accession 
number GSE34206). i) Phagocytosis-related genes were separated into those with significant changes in red, and those with no change 
following radiation (blue). ii) Graph shows normalized gene expression of individual phagocytosis-related genes that significantly change 
following radiation therapy, sorted by initial expression level. b. Expression of Mertk, Tyro3 Axl and Gas6 in murine immune cell 
populations analyzed by the Immunological Genome Project Consortium. c. Average expression of Mertk from the datasets shown in b), 
grouped by defined dendritic cell, macrophage, monocyte and neutrophil subsets.
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Figure 2: Ligation of Mertk results in a switch to suppressive cytokine patterns via upregulation of NF-kB p50. a. Bone 
marrow macrophages were left untreated or treated with Gas6 for 24 hours then left untreated or stimulated with LPS for a further 24 hours. 
Secretion of i) VEGF and ii) IL-12 was determined by cytokine bead assay. b. Bone marrow macrophages were left untreated, treated 
with IFNγ+LPS to drive M1 differentiation, IL-4 to drive M2 differentiation, or Gas6. Lysates were prepared after 24 hours and analyzed 
for expression of iNOS, Arginase I and GAPDH loading control. c. Bone marrow macrophages from wild-type or Mertk-/- mice were left 
untreated or treated with Gas6 for 15 or 30 minutes, lysed and analyzed for phospho-ERK or GAPDH loading control by western blotting. 
d. Bone marrow macrophages from wild-type or Mertk-/- mice were left untreated or treated with Gas6 for 24 hours, lysed and analyzed for 
NF-kB p50, NF-kB p65 or GAPDH loading control by western blotting. e. Bone marrow macrophages were left untreated or treated with 
Gas6 for 24 hours then treated with an NF-kB p50 inhibitor peptide or scrambled control peptide and stimulated with LPS for a further 24 
hours. Secretion of VEGF was determined by cytokine bead assay. f. Wild-type or NFKB1-/- mice were irradiated with 9.5Gy total body 
radiation and reconstituted with bone marrow from wild-type (wt) or NFKB1-/- mice to create four types of bone marrow chimeras: wt 
bone marrow (BM) and wt stroma (ST) – circles; NFKB1-/- BM and NFKB1-/- ST – squares; wt BM and NFKB1-/- ST – upward triangles; 
or NFKB1-/- BM and wt ST – downward triangles. Following reconstitution mice were challenged with Panc02 tumors and at d14 left 
untreated (open shapes) or treated with 20Gy x3 focal RT (filled shapes). Graphs show i) average tumor diameter or ii) overall survival. 
Results are representative of two or more experimental repeats of 6-8 mice per group. Key: *=p<0.05; **=p<0.01; NS = not significant.
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marrow chimeras where wild-type mice were given bone 
marrow from wild-type controls or NFκB1-/- mice, and 
NFκB1-/- mice were given bone marrow from NFκB1-/-  
controls or wild-type mice. Once reconstituted, mice 
were challenged with Panc02 pancreatic adenocarcinoma 
tumors and then treated with radiation therapy (Figure 2f). 
As expected, radiation therapy causes a transient growth 
delay in wild-type mice, but in NFκB1-/- mice radiation 
therapy results in tumor cures [18]. Importantly, this effect 
was entirely dependent on bone-marrow derived cells, 
such that wild-type mice with NFκB1-/- bone marrow 
were cured by radiation therapy, while NFκB1-/- mice 
with wild-type bone marrow exhibited only a growth 
delay (Figure 2f). These data demonstrate that activation 
of Mertk alters the cytokine response of macrophages 
via accumulation of NFκB p50, and that preventing 
NFκB p50 accumulation in hematopoietic cells through 
NFκB1-/- dramatically improves the response to radiation 
therapy.
Chimeric mice established with Mertk-/- bone 
marrow have been shown to have delayed tumor formation 
compared to mice with wild-type bone marrow [51]. 
This was associated with early inflammation in the tumor 
implantation site of mice with Mertk-/- bone marrow 
resulting in a CD8 T cell suppression of tumor growth 
[51]. To determine whether the absence of Mertk affects 
tumor growth or the response to radiation therapy, we 
established CT26 colorectal carcinoma in wild-type 
BALB/c or BALB/c Mertk-/- mice and Panc02 pancreatic 
adenocarcinoma, 3LL lung adenocarcinomas, and B16 
melanoma in wild-type C57BL/6 or C57BL/6 Mertk-/- 
mice. Tumor growth was unaffected in Mertk-/- mice 
on either background with any of the cell lines tested 
(Figure 3a). To determine the effect of Mertk on metastases, 
we used the 4T1 mammary carcinoma model in BALB/c 
mice, which has a high rate of spontaneous metastases 
(Figure 3b). We found that as in the other models, tumor 
growth was not affected in Mertk-/- mice and the number 
of lung metastases was also not affected in mice lacking 
Mertk (Figure 3b). These data demonstrate that in a wide 
range of models in two different genetic backgrounds 
in our laboratory, the absence of Mertk does not affect 
tumor growth, progression or spontaneous metastases. To 
deliver a high rate of cell death into these tumors, CT26 
tumor-bearing mice were treated with CT-guided radiation 
therapy to deliver therapeutic doses of radiation to the 
tumor while avoiding radiosensitive tissues (Figure 3c). 
As expected, radiation therapy resulted in transient control 
of CT26 tumors in wild-type mice followed by recurrence 
in 11 of 12 animals. However, in Mertk-/- mice radiation 
therapy resulted in complete tumor regression in 9 of 
11 animals (Figure 3c). These data demonstrate that the 
loss of Mertk results in significantly enhanced survival of 
mice following radiation therapy. This does not occur in 
untreated mice, but occurs as a result of complete tumor 
cure after treatment of Mertk-/- mice with radiation therapy 
as compared to transient tumor control followed by 
outgrowth in wild-type mice.
Surprisingly, in the Panc02 pancreatic 
adenocarcinoma model the effect of radiation therapy was 
not significantly different in Mertk-/- mice from wild-type 
mice (Figure 4a). We have seen similarly divergent results 
in prior studies with CT26 and Panc02: CT26 tumors were 
highly responsive to TGFβR blockade in combination with 
radiation therapy, while Panc02 tumors remained poorly 
responsive to radiation therapy despite an improved 
immune environment following TGFβR blockade [52]. 
Exposure to TGFβ diverts macrophage pro-inflammatory 
responses towards M2-type responses [53, 54]; however, 
in in the CT26 tumor model, TGFβR blockade appeared 
to function mainly by improving CD8 T cell control of 
tumors [52]. We hypothesized that in the poorly responsive 
Panc02 pancreatic adenocarcinomas, both Mertk and 
TGFβ were acting together to suppress local immune 
responses by driving suppressive differentiation of tumor 
macrophages. To test whether Mertk and TGFβ act in 
combination, we made use of Raw264.7 macrophages that 
strongly repolarize from a constitutive M1 differentiation 
and cytokine pattern to M2 differentiation and cytokine 
pattern on exposure to irradiated cancer cells [18]. 
Treatment of Raw264.7 macrophages with TGFβ was 
also able to divert to IL-10 production rather than TNFα 
following LPS stimulation (Figure 4b), confirming the 
suppressive effect of TGFβ in this in vitro model. In our 
prior studies, treatment of macrophages with TGFβ did 
not affect expression of iNOS or arginase, nor was it able 
to change the ability of IFNg and LPS to induce iNOS or 
IL-4 to induce arginase [52]. Thus, like Gas6, treatment of 
macrophages with TGFβ1 resulted in altered macrophage 
cytokine responses without changing expression of the 
prototypical effector molecules of M1 or M2 differentiated 
cells. The presence of a specific TGFβR inhibitor was able 
to inhibit the conversion to IL-10 production by irradiated 
cancer cells (Figure 4c); however, the TGFβR inhibitor 
was not able to restore TNFα production by macrophages 
(Figure 4c). To test the combination with Mertk inhibition, 
we co-cultured irradiated cancer cells with macrophages in 
the presence of a TGFβR inhibitor, a Mertk-Fc blocking 
antibody or the combination. We demonstrated that 
irradiated cancer cells redirect macrophages to secrete 
suppressive cytokines, and both Mertk-Fc and TGFβR 
inhibitor partially block suppressive cytokine secretion 
(Figure 4d), but that the combination of the TGFβR 
inhibitor together with a blocking MertkFc fusion protein 
was able to completely inhibit the co-culture induced 
switch to IL-10 production and importantly was able to 
restore TNFα production in response to LPS stimulation 
(Figure 4d). These data demonstrate that Mertk ligation 
and TGFβ each individually prevent proinflammatory 
differentiation of macrophages, and combined blockade 
permits proinflammatory differentiation even in the 
presence of dying cancer cells.
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In view of these data, we tested the effect of loss 
of Mertk and TGFβ signaling on radiation therapy 
of Panc02 tumors in vivo. To block TGFβ in vivo we 
treated wild type or Mertk knockout mice with the orally 
bioavailable small molecule TGFβR1 inhibitor SM16 
[52] for two weeks following treatment with radiation 
therapy (Figure 5). As before, tumor growth and therapy 
were identical in wild-type and Mertk-/- mice (Figure 5) 
and as we have previously shown, TGFβR inhibition 
alone did not significantly alter tumor growth [52]. When 
combined with radiation therapy, TGFβR inhibition 
extended survival in wild-type mice but in Mertk-/- mice 
TGFβR inhibition was dramatically more effective 
and resulted in tumor cures (Figure 5b). Importantly, 
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Mertk-/- mice were challenged with CT26 colorectal carcinoma, or C57BL/6 wild-type or C57BL/6 Mertk-/- mice were challenged with ii) 
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this combination of Mertk-/- and TGFβR inhibition 
did not affect tumor growth unless radiation therapy 
was present, suggesting that the large-scale cell death 
induced by radiation therapy was required to initiate this 
response. During tumor rejection, Mertk-/- mice treated 
with TGFβR inhibitors frequently exhibited either moist 
or dry desquamation in the radiation field that was 
not seen to any significant degree in any other group. 
This increased toxicity of radiation therapy resolved 
over time and resulted in a scarred treatment site but 
no other detectable problems in survivor mice. These 
data demonstrate that radiation therapy in the presence 
of combined loss of Mertk and TGFβR signaling is 
curative even in a highly unresponsive pancreatic 
adenocarcinoma, and demonstrates that therapeutically 
manipulating the macrophage response to dying cells in 
the tumor environment is a potential strategy to enhance 
the efficacy of radiation therapy.
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DISCUSSION
Tumor-associated macrophages are linked to poor 
prognosis in cancer patients, and represent a tempting 
therapeutic target. In the field of tumor immunotherapy 
in particular, there is generally an interrelationship 
between tumor macrophages and T cells, such that 
tumor macrophages can potently suppress T cell targeted 
immunotherapies [15, 55, 56]. This suppression of T cells by 
macrophages may be a critical component of inflammatory 
resolution and wound healing under normal conditions, 
but is also triggered by damage to the tumor environment. 
Our studies thus far indicate that the macrophage response 
to cancer cell death following cytotoxic therapy results 
in a shift to wound healing in the tumor environment 
that permits recurrence and outgrowth of residual cancer 
cells [18, 47]. Other groups have shown that decreasing 
the number of tumor macrophages by targeting CSF1R 
has proven to be an effective combination with both 
chemotherapy and radiation therapy [15, 16, 35, 37, 56]. 
Those macrophages that remain following CSF1R therapy 
are less suppressive [56]; however, it is noticeable that this 
therapeutic combination does not provide cures [15, 16, 35, 
37, 56]. We hypothesize that while depletion only removes 
the negative signal, repolarizing macrophages to a pro-
inflammatory state provides an additional positive signal 
that supports tumor clearance.
The Mertk receptor represents a very interesting 
therapeutic target both due to its highly specific expression 
on macrophages, and its role in the response to dying cells. 
Similar findings have been reported for MFG-E8, which 
also participates in the phagocytosis of apoptotic cells. 
Administration of MFG-E8 to macrophages suppresses 
proinflammatory responses [57, 58], and MFG-E8 
blocking antibodies while ineffective as single agents result 
in tumor control when combined with chemotherapy or 
radiation therapy [59]. Since MFG-E8 signaling occurs in 
part through Mertk [32], it is possible that Mertk knockout 
mice lose the effects of both MFG-E8 and Gas6 mediated 
recognition of apoptotic cells. In some circumstances, 
Mertk is ectopically expressed on cancer cells but not on 
normal cells [60, 61], making it an additionally relevant 
target. Small molecule drugs targeting Mertk and the 
TAM family member Axl are in development for patients 
with acute myeloid leukemia and acute lymphoblastic 
leukemia [62]. Based on the data presented here, we 
would propose that optimal clinical translation of these 
agents for patients with solid tumors including colorectal 
carcinoma and pancreatic adenocarcinoma would involve 
radiation therapy delivered during Mertk blockade. In 
addition, a novel class of therapeutic antibodies has been 
developed that blocks the recognition of dying cells by 
phagocytes [63]. These antibodies that bind to exposed 
phosphatidylserine (PS) either directly or via PS-binding 
proteins, have been shown to significantly enhance the 
efficacy of radiation therapy [64] and chemotherapy [65], 
and act to redirect suppressive macrophage polarization 
[66]. The PS-targeting antibody Bavituximab is in late 
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phase clinical trials in combination with cytotoxic therapy. 
However, as we have demonstrated, in some settings 
Mertk blockade is not sufficient to restore inflammatory 
functions in macrophages and is not sufficient for efficacy. 
We demonstrate that small molecule inhibition of TGFβR 
is a dramatically effective partner when combined with 
loss of Mertk signaling and would be an interesting 
combination for further development. Our prior studies 
demonstrated that the combination of small molecule 
inhibition of TGFβR with radiation therapy in responsive 
tumors resulted in a reduction in T regulatory cells in the 
tumor and efficacy was entirely dependent on CD8 T cells 
[52]; thus, it is possible that the in vivo function of TGFβ 
inhibition includes additional mechanisms in addition to, 
or instead of changing the macrophage response to dying 
cells. This is an area of ongoing study.
Mertk ligation has been shown to activate the 
MEK-ERK-Tpl2- NFκB p105 complex, and Mertk 
ligation has been shown to block conventional p50:p65 
NFκB signaling [67]. Our data also demonstrates that 
NFκB p50 accumulation may be a mechanism of action 
of Mertk ligation and confirms both Mertk and NFκB1 
p50 as potential target genes to improve tumor control to 
radiation therapy. It is particularly interesting that Mertk 
ligation changes the response of macrophages to stimuli 
without causing M1 or M2 polarization, via upregulation 
of NFκB p50. However, high NFκB p50 expression is 
also a feature of M2-polarized tumor macrophages [68] 
and LPS tolerized macrophages [69]. It is possible that 
in these circumstances ligation of Mertk by Gas6 on 
apoptotic cells may provide little additional signal to 
these previously polarized macrophages, but this remains 
to be determined. In view of these data, it is important to 
note that since subtle changes in the proportion of NFκB 
signaling molecules can alter the response of otherwise 
identical macrophages this may limit our ability to 
predict macrophage responses to stimuli based on surface 
phenotyping alone.
Though the responses are compelling, toxicity is 
increased where both Mertk and TGFβR signaling are 
blocked. In our model, close targeting of the tumor using 
CT-guided therapy limited the consequences to the animal; 
however it is possible that this strategy is too toxic for 
treatment plans with significant doses to critical structures. 
In our studies we are using high hypofractionated doses to 
model SBRT based on our combination immunotherapy 
studies in stage IV melanoma patients [48]. One distinction 
between our studies and patients treated at these doses is 
that while patients have local response rates of over 90% 
to metastases in the lung or liver [48, 70], in the mouse 
we see consistent local failure with radiation alone. In the 
setting of effective local control in patients it is likely most 
important to leverage locally generated immune responses 
to affect distant, untreated tumors and microscopic disease 
which is an extremely rare event in the absence of systemic 
therapy [71]. We believe that short course radiation 
represents a superior partner for immunotherapies to avoid 
repeated kill of lymphocytes [72] and provides acute rather 
than chronic antigen release. However, we also suspect 
that high, hypofractionated doses engender a stronger 
tissue repair response that limits the adaptive immune 
response. It remains to be determined whether changing 
the dose and fractionation of radiation changes the 
efficacy of loss of Mertk combined with TGFβ blockade 
and whether it changes the toxicity to normal tissue. This 
is an area of ongoing study. Similarly, it remains to be 
seen if other cytotoxic therapies such as chemotherapy 
will show enhanced efficacy when combined with loss of 
Mertk. Despite tumor cure in Mertk-/- mice, in the days 
immediately prior to cure we do not see evidence of 
increased T cell infiltration into the tumor compared to 
wild-type mice (data not shown). We believe this is due 
to loss of Mertk resulting in decreased T cell suppression 
in the tumor environment rather than increased numbers 
of T cells, but the contribution of adaptive immune cells 
remains to be determined, including potential effects on 
distant, untreated tumors.
The data presented here show the dramatic 
difference between the fact of radiation-induced cancer 
cell death and the response of the host to cell death. 
Irradiated cancer cells are known to display a small-
scale early apoptotic response to radiation therapy, but 
then the remaining cells die a slower clonogenic death 
through mitotic catastrophe. Thus, radiation results in a 
chronic exposure to dying cells. It is possible that since 
phagocytosis of dying cells is impacted, dying cancer 
cells will proceed to secondary necrosis with associated 
release of proinflammatory adjuvants. We and others 
have previously demonstrated that macrophages are 
critical sensors of apoptotic versus necrotic cells and 
engineering non-apoptotic cell death of cancer cells 
significantly improves anti-tumor immune control of 
tumors [3, 5, 73]. It is possible that strategies that increase 
levels of cell death in response to cytotoxic therapies will 
have only incremental increases in efficacy unless they 
reach the point where all cells are killed, whereas our data 
shows that changing the host response to cell death has 
the potential to dramatically change outcomes without 
changing the number of dying cells.
MATERIALS AND METHODS
Ethics
All animal protocols were approved by the Earle 
A. Chiles Research Institute IACUC (Animal Welfare 
Assurance No. A3913-01).
Animals and cell lines
The CT26 murine colorectal carcinoma [39] 
(BALB/c), the 4T1 mammary carcinoma cell line [40] 
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(BALB/c), the B16 melanoma (C57BL/6), Raw264.7 
monocyte/macrophage cell line [41] (C57BL/6), and the 
3LL lung adenocarcinoma [42] (C57BL/6) were obtained 
from the ATCC (Manassas, VA). The Panc02 murine 
pancreatic adenocarcinoma cell line [43] (C57BL/6) 
was kindly provided by Dr. Woo (Mount Sinai School 
of Medicine, NY). Six-8 week old C57BL/6 mice and 
BALB/c were obtained from Charles River Laboratories 
(Wilmington, MA) for use in these experiments. Mice 
lacking Mertk (Mertk-/-) [29] were obtained from 
The Jackson Laboratories (Bar Harbor, Maine) and 
backcrossed greater than 8x to C57BL/6 or BALB/c 
mice using genotyping from Transnetyx (Cordova, 
TN) and selection of breeder mice with the optimum 
genetic background using speed congenic services from 
Dartmouse (Lebanon, NH).
Reagents
The orally bioavailable small molecule inhibitor 
of TGFβ, SM16, was obtained under a material transfer 
agreement from Biogen Idec (Cambridge, MA) and was 
incorporated into standard Purina rodent chow (#5001) by 
Research Diets (New Brunswick, NJ) at a concentration of 
0.3 g SM16 per kg chow (0.03%) as previously described 
[44]. A calorie and nutrient-matched diet without SM16 
(Purina) was used as the control diet. The Mertk-Fc fusion 
protein and recombinant Gas6 were obtained from R&D 
systems (Minneapolis, MN). Recombinant TGFβ1, IFNγ 
and IL-4 were obtained from Ebioscience (San Diego, 
CA). Ultrapure LPS was obtained from InVivogen (San 
Diego, CA).
Gene expression analysis
The results of gene expression analysis of tumor-
infiltrating macrophages has previously been published 
[18] and gene expression data has been uploaded to GEO 
(Accession number GSE34206). Data was analyzed 
using GeneSifter (Geospiza Inc, Seattle, WA) to generate 
normalized gene expression profiles of each treatment 
condition and used to identify phagocytosis-related 
genes with significant changes between treatment groups. 
Analysis of pathway interactions was performed using 
Cytoscape [45]. Analysis of gene expression in immune 
cell populations was performed on data generated by The 
Immunological Genome Project Consortium [46] and 
analyzed using tools provided at www.immgen.org.
Ex vivo macrophage treatments
To generate bone marrow-derived macrophages, 
bone marrow cells isolated from long-bones of wild-
type or Mertk-/- mice were cultured for a total of 
7 days in complete media containing 40ng/ml MCSF 
(Ebioscience), with additional growth medium provided 
after 3 days of culture. Adherent cells were harvested 
and macrophage differentiation confirmed by flow 
cytometry for CD11b, F4/80, Gr1 and IA. Macrophages 
were differentiated into M1 or M2 phenotypes by 
culturing for 24 hours in the presence of 10ng/ml 
IFNγ + 1μg/ml LPS or 10ng/ml IL-4, respectively as 
previously described [47], or treated with 500μg/ml 
recombinant Gas6. For co-culture, Panc02 or 4T1 cells 
were irradiated with 10Gy of radiation using a cesium 
source, and 1 × 104 cancer cells were co-cultured with 
1 × 104 Raw264.7 cells or 2 × 104 primary bone marrow 
macrophages in the presence or absence of TGFβ1, 
Mertk-Fc or Gas6 in replicate wells of 96-well u-bottom 
plates for 24 hours before treatment with 100ng/ml LPS. 
Supernatants were collected after a further 48 hours 
and tested for cytokine levels by ELISA using matched 
antibody pairs specific for TNFα and IL-10 (R&D 
Systems, Minneapolis, MN) against a standard curve 
of recombinant cytokine or using custom cytokine bead 
assays (Life Technologies, Grand Island, NY) run on a 
Luminex 100 array reader.
Western blotting
Cells were lysed in RIPA buffer and denatured in 
SDS loading buffer containing beta 2-mercaptoethanol, 
electrophoresed on 10% SDS-PAGE gels and transferred 
to nitrocellulose. Blocked blots were probed overnight at 
4°C with primary antibodies followed by HRP-conjugated 
secondary antibodies. Binding was detected using a Pierce 
SuperSignal Pico Chemiluminescent Substrate (Thermo 
Fisher Scientific, Rockford, IL) and exposure to film.
CT-guided radiation therapy of tumors in mice
Tumors were inoculated s.c. in the right flank and 
allowed to establish for 10–14 days before initiation of 
treatment. Radiation was delivered using the Small Animal 
Radiation Research Platform (SARRP, XStrahl, Gulmay 
Medical, Suwanee, GA). Using a cone-beam CT scan with 
360 projections, the tumor was visualized, the isocenter 
was placed within the tumor and a 10 × 10mm or 5 × 5mm 
collimator was utilized to deliver radiation. Dosing was 
based on recent clinical studies [48], with one to three 
daily 20Gy treatment fractions. Where specified, SM16 
was present in the diet for two weeks following radiation 
therapy before return to normal diet in all groups.
Cytokine bead assay
Tumors were harvested on ice and homogenized in 
4.5μl PBS containing 1x HALT protease inhibitor (Thermo 
Fisher Scientific) per mg tissue. The cell debris was 
removed by centrifugation at 14000 x g for 15 minutes 
at 4°C, and supernatants were stored in aliquots at 
−80°C until used. Cytokine levels in the supernatants 
were detected using a murine multiplex bead assay (Life 
Technologies, Grand Island, NY) and read on a Luminex 
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100 array reader. Cytokine concentrations for replicates of 
each tumor sample were calculated according to a standard 
curve.
Statistics
Data were analyzed and graphed using Prism 
(GraphPad Software, La Jolla, CA). Individual data sets 
were compared using Student’s t-test and analysis across 
multiple groups was performed using ANOVA with 
individual groups assessed using Tukey’s comparison. 
Kaplan Meier survival curves were compared using a log-
rank test.
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